U.S. flag An official website of the United States government
  1. Home
  2. Drugs
  3. News & Events for Human Drugs
  4. Development of Antiviral Drugs for the Treatment of Adenoviral Infection in Immunocompromised Patients - 08/08/2019 - 08/08/2019
  1. Drugs

Public

Event Title
Development of Antiviral Drugs for the Treatment of Adenoviral Infection in Immunocompromised Patients
August 08, 2019

Canceled

Development of Antiviral Drugs for the Treatment of Adenoviral Infection in Immunocompromised Patients - 08/08/2019 - 08/08/2019


This workshop is cancelled for the time being and will be rescheduled for a later time

Summary: The Food and Drug Administration is announcing the following public workshop titled “Development of Antiviral Drugs for the Treatment of Adenoviral Infection in Immunocompromised Patients." The purpose of the public workshop is to discuss the scientific and clinical trial design considerations for development of antiviral products to treat adenoviral infection.

Date and Time: The public workshop will be held on August 8, 2019 from 8:30 a.m to 4:30 p.m.

Location: The workshop will be held at FDA's White Oak campus, 10903 New Hampshire Ave., Building 31 Great Room, Silver Spring, MD 20993. Entrance for the public workshop participants (non-FDA employees) is through Building 1 where routine security check procedures will be performed. For parking and security information, please refer to Public Meetings at the FDA White Oak Campus.

Requests for Oral Presentations: During online registration you may indicate if you wish to present during a public comment session or participate in a specific session, and which topic(s) you wish to address. We will do our best to accommodate requests to make public comments. Individuals and organizations with common interests are urged to consolidate or coordinate their presentations, and request time for a joint presentation, or submit requests for designated representatives to participate in the focused sessions. Following the close of registration, we will determine the amount of time allotted to each presenter and the approximate time each oral presentation is to begin, and will select and notify participants by August 2, 2019. All requests to make oral presentations must be received by the close of registration on July 29, 2019. If selected for presentation, any presentation materials must be emailed to ONDPublicMTGSupport@fda.hhs.gov no later than August 5, 2019. No commercial or promotional material will be permitted to be presented or distributed at the public workshop.

Registration: Persons interested in attending this public workshop must register online by August 1, 2019, midnight Eastern Standard time. To register, please provide complete contact information for each attendee, including name, title, affiliation, address, email, and telephone to https://www.eventbrite.com/e/development-of-antiviral-drugs-for-the-treatment-of-adenoviral-infection-in-immunocompromised-tickets-55714561754. Onsite registration on the day of the meeting will be provided based on space availability. Requests for Oral Presentations: During online registration you may indicate if you wish to present during a public comment session or participate in a specific session, and which topic(s) you wish to address. We will do our best to accommodate requests to make public comments. Individuals and organizations with common interests are urged to consolidate or coordinate their presentations, and request time for a joint presentation, or submit requests for designated representatives to participate in the focused sessions. Following the close of registration, we will determine the amount of time allotted to each presenter and the approximate time each oral presentation is to begin, and will select and notify participants by August 2, 2019. All requests to make oral presentations must be received by the close of registration on July 29, 2019. If selected for presentation, any presentation materials must be emailed to ONDPublicMTGSupport@fda.hhs.gov no later than August 5, 2019. No commercial or promotional material will be permitted to be presented or distributed at the public workshop.

Contact: If further information is needed, please contact Lori Benner and/or Jessica Barnes, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 22, rm. 6221, Silver Spring, MD 20993-0002, 301-796-1300.

Streaming Webcast: This public workshop will be webcasted at https://collaboration.fda.gov/oapdavp080819 . If you have never attended a Adobe Connect Pro event before, test your connection at https://collaboration.fda.gov/common/help/en/support/meeting_test.htm. To get a quick overview of the Connect Pro program, visit https://www.adobe.com/go/connectpro_overview.
 
Meeting Materials: The agenda, speaker presentation, and other meeting material will be posted here a few days prior to the workshop. Please note that only printed copies of the agenda, affiliations and disclosures will be provided during the meeting. Please print/bring your own slides, as these will not be provided on the day of the meeting as printed copies.
 
Webcast Recordings: A recording(s) of the workshop will be posted here shortly after the completion of the workshop.
 
Transcripts: Transcripts of the workshop will be posted here approximately 30-45 days after the completion of the workshop.

Back to Top